People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Summary

The primary outcome measure is PIRA (progression independent of relapse activity), based primarily on clinical assessment, dichotomized as present or not. For Aim 1, the cohort, patient-derived disability status (PDDS) score, and ambulation score (self-reported) will be the primary endpoints of interest. For Aim 2, the clinical trial, PIRA will be measured pre-GLP-1 start and at study end (week 72). A composite score of disability, similar to the ORATORIO13 trial will be constructed including EDSS score, 25-foot timed walk, 9-hole peg test, and SDMT score.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Multiple Sclerosis

Eligibility basics and study details

Study type

Observational

Phase

Not applicable

Ages

18 to 70 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Northwestern University

Last updated on ClinicalTrials.gov

March 17, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites